Israpafant
Alternative Names: Pafnol; Y 24180Latest Information Update: 10 Oct 2003
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Japan Tobacco; Mitsubishi Pharma Corporation
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 10 Oct 2003 No development reported - Preregistration for Asthma in Japan (PO)
- 06 Apr 2000 Yoshitomi is now called Welfide Corporation
- 13 May 1998 Preregistration for Asthma in Japan (PO)